As I have written about previously, the IP and competitive landscape for mRNA and lipid nanoparticles is complex. Pioneers, mid-stage, and new market entrants must take careful consideration of this landscape and develop a...more
Partner Dan Shores will present a webinar titled "The mRNA/Lipid Nanoparticle Competitive and Litigation Landscape" for Medmarc, the leading expert in the products liability risks facing medical technology and life sciences...more
8/22/2023
/ Competition ,
Coronavirus/COVID-19 ,
Health Care Providers ,
Health Technology ,
Intellectual Property Protection ,
Life Sciences ,
Medical Technology Companies ,
Moderna Inc. ,
Patent Litigation ,
Pfizer ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Regulatory Approval ,
Webinars
In Part I of this series providing a summary of the mRNA IP and competitive landscape through one year of the COVID-19 pandemic, we focused on market players BioNTech, Moderna and CureVac; in Part II, we discussed Translate...more
Founders of an emerging company must decide early on in its growth cycle whether to require employees to assign their inventions (including rights to patent and patent applications –collectively “patent rights”) to the...more
3/29/2021
/ Artificial Intelligence ,
Assignments ,
Confidential Information ,
Fiduciary Duty ,
Intellectual Property Protection ,
Inventors ,
Joint Inventors ,
Patent Applications ,
Patents ,
Trade Secrets ,
USPTO
Founders of technology-based companies often recognize very early on that their company’s IP and related technology comprise a significant or even central part of the company’s overall value. Determining how to best protect...more